GT-201 is under clinical development by Shanghai Grit Biotechnology and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GT-201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GT-201 overview

GT-201 is under development for the treatment of hepatocellular carcinoma, recurrent, cervical cancer, ovarian cancer, endometrial cancer, gynecological cancer, non-small cell lung cancer and metastatic melanoma solid tumors. The therapeutic candidate comprises of GT201 autologous tumor infiltrating lymphocytes (TILs). It is administered through parenteral and intravenous drip route.

Shanghai Grit Biotechnology overview

Shanghai Grit Biotechnology engaged in developing and producing cell drugs with focus in the field of tumor immunotherapy. The company is headquartered in Shanghai City, Shanghai, China.

For a complete picture of GT-201’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.